Cargando…
Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study
Type I gastric neuroendocrine neoplasms (gNENs) are associated with atrophic gastritis and have a high recurrence rate, which means frequent endoscopies are required. The objective of this study was to identify factors predicting the local recurrence of type I gNENs. The clinical course and the path...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045191/ https://www.ncbi.nlm.nih.gov/pubmed/36979807 http://dx.doi.org/10.3390/biomedicines11030828 |
_version_ | 1784913541155782656 |
---|---|
author | Sheikh-Ahmad, Mohammad Saiegh, Leonard Shalata, Anan Bejar, Jacob Kreizman-Shefer, Hila Sirhan, Majd F. Matter, Ibrahim Swaid, Forat Laniado, Monica Mubariki, Nama Rainis, Tova Rosenblatt, Ilana Yovanovich, Ekaterina Agbarya, Abed |
author_facet | Sheikh-Ahmad, Mohammad Saiegh, Leonard Shalata, Anan Bejar, Jacob Kreizman-Shefer, Hila Sirhan, Majd F. Matter, Ibrahim Swaid, Forat Laniado, Monica Mubariki, Nama Rainis, Tova Rosenblatt, Ilana Yovanovich, Ekaterina Agbarya, Abed |
author_sort | Sheikh-Ahmad, Mohammad |
collection | PubMed |
description | Type I gastric neuroendocrine neoplasms (gNENs) are associated with atrophic gastritis and have a high recurrence rate, which means frequent endoscopies are required. The objective of this study was to identify factors predicting the local recurrence of type I gNENs. The clinical course and the pathological and biochemical data of patients with type I gNENs treated at Bnai Zion Medical Center between 2006 and 2022 were analyzed retrospectively. Twenty-seven type I gNENs were evaluated. The follow-up period was 41 months (range: 11–288 months). Recurrence of the tumor occurred in 13/27 (48%) patients after 35 months (median (M), interquartile range (IQR): 21–67.5). Serum gastrin levels were significantly higher in patients with recurrent disease versus patients with non-recurrent disease (788 vs. 394 ng/L; p = 0.047), while the Ki-67 index was significantly lower in patients with recurrent disease versus patients with non-recurrent disease (1% vs. 3.5%; p = 0.035). Tumor size, mitotic count, and serum chromogranin A levels did not correlate with recurrence. The present study emphasizes the role of gastrin in the pathogenesis of gNEN recurrence and highlights the debate regarding the ability of the Ki-67 index to predict the clinical course of this disease. |
format | Online Article Text |
id | pubmed-10045191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100451912023-03-29 Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study Sheikh-Ahmad, Mohammad Saiegh, Leonard Shalata, Anan Bejar, Jacob Kreizman-Shefer, Hila Sirhan, Majd F. Matter, Ibrahim Swaid, Forat Laniado, Monica Mubariki, Nama Rainis, Tova Rosenblatt, Ilana Yovanovich, Ekaterina Agbarya, Abed Biomedicines Article Type I gastric neuroendocrine neoplasms (gNENs) are associated with atrophic gastritis and have a high recurrence rate, which means frequent endoscopies are required. The objective of this study was to identify factors predicting the local recurrence of type I gNENs. The clinical course and the pathological and biochemical data of patients with type I gNENs treated at Bnai Zion Medical Center between 2006 and 2022 were analyzed retrospectively. Twenty-seven type I gNENs were evaluated. The follow-up period was 41 months (range: 11–288 months). Recurrence of the tumor occurred in 13/27 (48%) patients after 35 months (median (M), interquartile range (IQR): 21–67.5). Serum gastrin levels were significantly higher in patients with recurrent disease versus patients with non-recurrent disease (788 vs. 394 ng/L; p = 0.047), while the Ki-67 index was significantly lower in patients with recurrent disease versus patients with non-recurrent disease (1% vs. 3.5%; p = 0.035). Tumor size, mitotic count, and serum chromogranin A levels did not correlate with recurrence. The present study emphasizes the role of gastrin in the pathogenesis of gNEN recurrence and highlights the debate regarding the ability of the Ki-67 index to predict the clinical course of this disease. MDPI 2023-03-09 /pmc/articles/PMC10045191/ /pubmed/36979807 http://dx.doi.org/10.3390/biomedicines11030828 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sheikh-Ahmad, Mohammad Saiegh, Leonard Shalata, Anan Bejar, Jacob Kreizman-Shefer, Hila Sirhan, Majd F. Matter, Ibrahim Swaid, Forat Laniado, Monica Mubariki, Nama Rainis, Tova Rosenblatt, Ilana Yovanovich, Ekaterina Agbarya, Abed Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study |
title | Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study |
title_full | Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study |
title_fullStr | Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study |
title_full_unstemmed | Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study |
title_short | Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study |
title_sort | factors predicting type i gastric neuroendocrine neoplasia recurrence: a single-center study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045191/ https://www.ncbi.nlm.nih.gov/pubmed/36979807 http://dx.doi.org/10.3390/biomedicines11030828 |
work_keys_str_mv | AT sheikhahmadmohammad factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT saieghleonard factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT shalataanan factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT bejarjacob factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT kreizmansheferhila factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT sirhanmajdf factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT matteribrahim factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT swaidforat factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT laniadomonica factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT mubarikinama factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT rainistova factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT rosenblattilana factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT yovanovichekaterina factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy AT agbaryaabed factorspredictingtypeigastricneuroendocrineneoplasiarecurrenceasinglecenterstudy |